# In Situ Immune Parameters and Their Prognostic Role on the Survival of Patients With Glioblastoma

> **NCT03481231** · — · COMPLETED · sponsor: **Centre Georges Francois Leclerc** · enrollment: 160 (actual)

## Conditions studied

- Glioblastoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03481231
- **Lead sponsor:** Centre Georges Francois Leclerc
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-13
- **Primary completion:** 2024-09-14
- **Final completion:** 2024-09-14
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2025-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03481231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03481231, "In Situ Immune Parameters and Their Prognostic Role on the Survival of Patients With Glioblastoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03481231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*